Dr. Le Moigne has been working in oncology drug development for over 13 years, with expertise in target validation, clinical candidate selection, PK/PD relationship, toxicology and biomarker development. Dr Le Moigne is currently the Senior Director of preclinical development and translational medicine of ESSA Pharma, a biotech company developping N-terminal domain inhibitors of the Androgen Receptor pathway, and is in charge of the preclinical developmenet of new molecules. Prior to joining ESSA, Dr. Le Moigne was Director of Pharmacology at Cleave, between 2012 and 2018, and was leading the preclinical effort developing first class p97 inhibitors in the clinic. Dr. Le Moigne held primary roles in research and development at Sanofi, In Paris and Boston. Dr. Le Moigne led groups that participated in target validation efforts of new kinase inhibitors, advanced small molecules and antibodies to preclinical development and supported the progression of Aflibercept, a VEGF Trap biologic, during its clinical development. He received his PhD in pharmacology from the University Paris XI, France and earned his BS degree in cellular physiology from the University of Bretagne Occidentale, France.
Saturday, May 4
1:00 PM – 3:00 PM